# Vistagen Therapeutics, Inc.: overview VTGN · Nasdaq · CIK 1411685 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/vtgn.md) · [Financials](/companies/vtgn/financials.md) · [Filings](/companies/vtgn/filings.md) · [Insiders](/companies/vtgn/insiders.md) Latest reported revenue: [$1.5m](/filings/0001628280-26-057116.md) for Q1 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001628280-26-057116). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [183](/filings/0001628280-25-052079.md) | [234](/filings/0001628280-26-007718.md) | [(15.0) d](/filings/0001628280-26-043271.md) | [244](/filings/0001628280-26-057116.md) | [258](/filings/0001628280-25-052079.md) | [303](/filings/0001628280-26-007718.md) | [465 d](/filings/0001628280-26-043271.md) | [1,476](/filings/0001628280-26-057116.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(7774.3%)](/filings/0001628280-25-052079.md) | [(6461.5%)](/filings/0001628280-26-007718.md) | [96633.3% d](/filings/0001628280-26-043271.md) | [(6477.0%)](/filings/0001628280-26-057116.md) | [(7772.5%)](/filings/0001628280-25-052079.md) | [(6450.8%)](/filings/0001628280-26-007718.md) | [(3595.1%) d](/filings/0001628280-26-043271.md) | [(904.3%)](/filings/0001628280-26-057116.md) | | Net margin | % | [(7082.5%)](/filings/0001628280-26-007718.md) | [(6020.9%)](/filings/0001628280-26-007718.md) | [90900.0% d](/filings/0001628280-26-043271.md) | [(6186.5%)](/filings/0001628280-26-057116.md) | [(7526.0%)](/filings/0001628280-26-007718.md) | [(6237.3%)](/filings/0001628280-26-007718.md) | [(3499.8%) d](/filings/0001628280-26-043271.md) | [(882.8%)](/filings/0001628280-26-057116.md) | | Diluted EPS | $ per share | [(0.42)](/filings/0001628280-25-052079.md) | [(0.46)](/filings/0001628280-26-007718.md) | not reported | [(0.47)](/filings/0001628280-26-057116.md) | [(0.54)](/filings/0001628280-25-052079.md) | [(0.45)](/filings/0001628280-26-007718.md) | not reported | [(0.30)](/filings/0001628280-26-057116.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | FY2026 (2026-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.1](/filings/0001437749-23-018793.md) | [(0.2)](/filings/0001437749-23-018793.md) | [1.1](/filings/0001411685-25-000041.md) | [0.5](/filings/0001628280-26-043271.md) | [1.3](/filings/0001628280-26-043271.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(4308.3%)](/filings/0001437749-23-018793.md) | [26109.3%](/filings/0001411685-24-000022.md) | [(3103.5%)](/filings/0001411685-25-000041.md) | [(11517.1%)](/filings/0001628280-26-043271.md) | [(5683.7%)](/filings/0001628280-26-043271.md) | | Net margin | % | [(4306.8%)](/filings/0001437749-23-018793.md) | [26100.4%](/filings/0001411685-24-000022.md) | [(2759.6%)](/filings/0001411685-25-000041.md) | [(10579.8%)](/filings/0001628280-26-043271.md) | [(5491.3%)](/filings/0001628280-26-043271.md) | | Diluted EPS | $ per share | not reported | [(8.51)](/filings/0001411685-24-000022.md) | [(1.52)](/filings/0001411685-25-000041.md) | [(1.67)](/filings/0001628280-26-043271.md) | [(1.83)](/filings/0001628280-26-043271.md) | | Free cash flow | $m | [(45.5)](/filings/0001437749-23-018793.md) | [(50.2)](/filings/0001411685-24-000022.md) | [(25.8)](/filings/0001411685-25-000041.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vtgn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $630.2k | 2,788,620 | | New +2,788,620 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $355.8k | 1,574,200 | | Unchanged | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $191.6k | 847,992 | | Added +378,373 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $165.1k | 730,500 | | Added +439,200 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $117.3k | 519,077 | | Unchanged | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $99.1k | 438,643 | | Added +161,533 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $95.5k | 415,400 | Call | Added +375,000 | | [LUMINUS MANAGEMENT LLC](/funds/1279151.md) | 2026-06-30 | $91.1k | 403,115 | | Added +7,062 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $82.5k | 365,002 | | Reduced −88,389 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $79.4k | 351,141 | | Reduced −400,000 | ## Recent filings [All 898 filings](/companies/vtgn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-09 | 21:15 ET | [8-K](/filings/0001628280-26-065559.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-065559 | | 2026-09-25 | 13:11 ET | [8-K](/filings/0001628280-26-063510.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-063510 | | 2026-09-24 | 11:05 ET | [8-K](/filings/0001628280-26-063316.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-063316 | | 2026-09-22 | 20:22 ET | [8-K](/filings/0001628280-26-063046.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-063046 | | 2026-09-11 | 23:24 ET | [8-K](/filings/0001628280-26-061445.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-061445 | | 2026-08-14 | 20:12 ET | [10-Q](/filings/0001628280-26-057116.md) | Quarterly report, period 2026-06-30 | 0001628280-26-057116 | | 2026-08-14 | 12:40 ET | [8-K](/filings/0001628280-26-056953.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-056953 | | 2026-08-06 | 20:16 ET | [8-K](/filings/0001628280-26-054341.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-054341 | | 2026-08-05 | 20:04 ET | [8-K](/filings/0001628280-26-053304.md) | 3.01 Delisting notice | 0001628280-26-053304 | | 2026-07-31 | 20:10 ET | [DEF 14A](/filings/0001628280-26-051404.md) | Proxy statement, period 2026-07-31 | 0001628280-26-051404 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2026](/filings/0001628280-26-043271.md), filed Jun 15, 2026. ## Forecast league Q2 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3b64c214-2232-4662-a30f-c3bc284313dd) ## About the filer - CIK: 1411685 - Tickers: VTGN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.